Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The primary drug candidate in its pipeline of complement-targeted therapeutics is narsoplimab, a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. We show 59 historical shares outstanding datapoints in our OMER shares outstanding history coverage, used to compute OMER market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OMER market cap history over the course of time is important for investors
interested in comparing OMER's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OMER versus a peer is one thing; comparing
OMER market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OMER can fluctuate over the course of history.
With this page we aim to empower investors researching OMER by allowing them to research the OMER market cap history. |
Free OMER Email Alerts:
Video: The Importance of Market Cap
